Patents by Inventor Sean Studer

Sean Studer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20250115915
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 10, 2025
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
  • PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20250073256
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Application
    Filed: May 24, 2024
    Publication date: March 6, 2025
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
  • Prekallikrein-modulating compositions and methods of use thereof
    Patent number: 12042509
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 23, 2024
    Assignee: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
  • COMPLEMENT FACTOR B-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240043836
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.
    Type: Application
    Filed: November 23, 2022
    Publication date: February 8, 2024
    Applicant: ADARx Pharmaceuticals, Inc
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Sean Studer, Kimberly Fultz, Jean da Silva Correia
  • ADAR DEPENDENT EDITING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230272391
    Abstract: Disclosed herein are compositions and methods for recruiting and using ADAR. In some aspects, compositions and methods for targeting ADAR activity to a desired region, sequence, or nucleotide are disclosed. In some aspects, compositions and methods for increasing the efficiency of directed ADAR editing are disclosed.
    Type: Application
    Filed: July 30, 2021
    Publication date: August 31, 2023
    Applicant: ADARx Pharmaceutical, Inc.
    Inventors: Zhen Li, Rui Zhu, Jean da Silva Correia, Kimberly Fultz, Sean Studer, Sam Lear
  • PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230158059
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 25, 2023
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer